Last reviewed · How we verify
TOP1630 0.1% Ophthalmic Solution TID OU — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TOP1630 0.1% Ophthalmic Solution TID OU (TOP1630 0.1% Ophthalmic Solution TID OU) — Topivert Pharma Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TOP1630 0.1% Ophthalmic Solution TID OU TARGET | TOP1630 0.1% Ophthalmic Solution TID OU | Topivert Pharma Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TOP1630 0.1% Ophthalmic Solution TID OU CI watch — RSS
- TOP1630 0.1% Ophthalmic Solution TID OU CI watch — Atom
- TOP1630 0.1% Ophthalmic Solution TID OU CI watch — JSON
- TOP1630 0.1% Ophthalmic Solution TID OU alone — RSS
Cite this brief
Drug Landscape (2026). TOP1630 0.1% Ophthalmic Solution TID OU — Competitive Intelligence Brief. https://druglandscape.com/ci/top1630-0-1-ophthalmic-solution-tid-ou. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab